Bessemer Group
FATE icon

Bessemer Group’s Fate Therapeutics FATE Stock Holding History

Bessemer Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-78
Closed -$3K – 1911
2022
Q1 		$3K Hold
78
– – ﹤0.01% 1673
2021
Q4 		$5K Hold
78
– – ﹤0.01% 1569
2021
Q3 		$5K Hold
78
– – ﹤0.01% 1507
2021
Q2 		$7K Hold
78
– – ﹤0.01% 1386
2021
Q1 		$6K Buy
+78
New +$7.47K ﹤0.01% 1370

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Bessemer Group's FATE Position: Q2 2022 in Review

Bessemer Group sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 78 shares — an estimated $3K sold.

Bessemer Group first reported a position in FATE in Q1 2021 and held it in 5 quarters. The position peaked at $7K in Q2 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Bessemer Group reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bessemer Group sold 78 Fate Therapeutics shares in Q2 2022, an estimated $3K.
  • Bessemer Group first reported a position in Fate Therapeutics in Q1 2021 and held it in 5 quarters.
  • Bessemer Group's Fate Therapeutics position peaked at $7K in Q2 2021.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Bessemer Group's 13F filing for Q2 2022, filed 10 Aug 2022.